KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Travere Therapeutics (TVTX) Receivables - Other (2018 - 2025)

Travere Therapeutics (TVTX) has disclosed Receivables - Other for 9 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables - Other fell 43.48% year-over-year to $1.3 million, compared with a TTM value of $1.3 million through Dec 2025, down 43.48%, and an annual FY2025 reading of $1.3 million, down 43.48% over the prior year.
  • Receivables - Other was $1.3 million for Q4 2025 at Travere Therapeutics, down from $1.5 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $4.6 million in Q4 2023 and bottomed at $900000.0 in Q4 2021.
  • Average Receivables - Other over 5 years is $2.4 million, with a median of $2.2 million recorded in 2024.
  • The sharpest move saw Receivables - Other skyrocketed 142.11% in 2023, then tumbled 50.0% in 2024.
  • Year by year, Receivables - Other stood at $900000.0 in 2021, then soared by 111.11% to $1.9 million in 2022, then surged by 142.11% to $4.6 million in 2023, then crashed by 50.0% to $2.3 million in 2024, then crashed by 43.48% to $1.3 million in 2025.
  • Business Quant data shows Receivables - Other for TVTX at $1.3 million in Q4 2025, $1.5 million in Q3 2025, and $1.5 million in Q2 2025.